In-depth guides
Plain-language guides organize the central questions around ibogaine, dementia, uncertainty, and safety. Our approach to independent information explains why clear sourcing and cautious interpretation matter when evidence is limited.
Independent information resource
Services
Guides, comparisons, and research summaries for people evaluating ibogaine claims in the context of dementia, cognitive health, and care decisions.
Evidence before claims
Safety awareness
Respect for caregivers
A careful starting point
A clinical brief, without clinical promises.
Sage Bracket helps people distinguish established dementia evidence from unproven ibogaine claims. It presents clear, cautious context on research, risks, and care decisions for people with dementia, families, caregivers, and anyone evaluating claims about ibogaine and cognitive health.
The main brief on ibogaine and dementia is designed as a starting point for orientation, not as an instruction to pursue treatment. Dementia describes a group of symptoms that affect memory, thinking, and daily function; the National Institute on Aging’s overview of dementia emphasizes the importance of identifying causes and discussing changes with a qualified health professional.
Information services
Tools for weighing a difficult claim.
Decision frameworks
Decision frameworks help families separate a claim, an unknown, a potential risk, and a question for a treating clinician. For context on experiences that may be described as treatment narratives, some readers encounter ibogaine trip reports; personal accounts are not clinical evidence.
Comparisons and glossaries
Comparisons clarify the difference between established dementia care, investigational ideas, and promotional language. This includes attention to withdrawal-related claims, which are discussed separately at ibogaine withdrawal information and should not be conflated with dementia treatment.
Research summaries and FAQs
Research summaries and FAQs identify what is known, what remains uncertain, and what a study would need to show. They can also help readers put international treatment marketing in perspective, including pages about ibogaine in Thailand or treatment centers in Canada.
Evidence first
A claim is not a finding.
Ibogaine is a psychoactive alkaloid associated with the iboga plant. The background description of ibogaine is useful for basic orientation, but it does not establish ibogaine as a treatment for dementia.
Our summaries distinguish biological plausibility, anecdotes, early-stage investigation, and clinical evidence. This matters because cognitive symptoms can have many causes, and reports of benefit do not answer questions about diagnosis, safety, dosing, durability, or who might be harmed.
Guided action
Questions worth keeping in view.
Is Sage Bracket offering medical or clinical care?
No. Sage Bracket is an independent information resource. It provides guides, comparisons, research summaries, glossaries, and FAQ collections; it does not diagnose, recommend treatment, or provide medical supervision.
How should a family use these materials?
Use them to prepare careful questions and to compare a claim against available evidence and safety concerns. Current information may be supplemented by topic-focused publications such as updates on ibogaine research and policy, while remembering that publication or discussion does not equal proof for dementia.
What comes before an ibogaine decision?
A careful clinical evaluation of new or worsening cognitive symptoms is important. The clinical evidence overview and safety considerations can help frame questions, but they cannot replace individualized care.